Recent Event

<>

February 9, 2017 - February 10, 2017

San Diego, CA

Diagnostics Coverage & Reimbursement Conference West

Attendee: Real Endpoints team

For the 11th edition of the Q1 Diagnostic Coverage & Reimbursement Conference, focus is set on defining value of diagnostics and evidence to demonstrate clinical utility and cost benefits from the payer’s perspective, in addition to accessing promising partnerships with insurers through alternate payment models, paving the way to satisfactory and expedited reimbursement. Through insightful case studies delivered by high level industry thought leaders but also panel and round table discussions involving payer organization coverage decision makers, the event will once more shed light onto solutions for critical areas of challenges in obtaining positive reimbursement with the most relevant strategies to further advance accurate testing in the healthcare market.

Recent Events

May 19, 2020 12:00pm ET

Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman

Real Endpoints

CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment

view event >

May 4, 2020 12:30pm ET

HBO show!

Chief Clinical Officer: Jane F. Barlow, MD, MPH, MBA

Real Endpoints

Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.

view event >

October 16, 2019 - October 18, 2019

New York, NY

Speaker: Jeff Berkowitz
Roger Longman

Real Endpoints

Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs

view event >

October 13, 2019 - October 15, 2019

Laguna Beach, CA

Panel: Drug Pricing and Value Based Reimbursement

Jeff Berkowitz

Real Endpoints

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

October 2, 2019 1:15pm

San Diego, CA

Roger Longman

Real Endpoints

Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.

view event >

May 31, 2019

Waldorf Astoria Chicago Hotel

5th Annual Immuno-Oncology BD&L and Investment Forum

Speaker: Roger Longman

Real Endpoints

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.